צמיחת הכנסות ב-12 חודשים נגררים: BeyondSpring Inc (BYSI)

BeyondSpring Inc. automates the search for oncology targets using AI and robotics. The current 12-month trailing revenue dynamics on this GURU.Markets chart illustrate expansion rates, where 0.00 captures the current state of the parameter. High FDA barriers and patent protection limit competition, although a liquidity deficit resulting from global operational costs necessitates a secondary offering.

BeyondSpring Inc. specializes in the development of plinabulin for the treatment of oncology and neutropenia. The rolling 12-month sales growth relative to the same period last year visualizes revenue expansion rates in real time. This metric measures the percentage deviation of current annual income from the corresponding period of the previous year. For BeyondSpring Inc., this is the primary marker of commercialization efficiency for its drugs in the US and China. A slowdown in growth signals business stagnation and risks of frozen investments.